Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
Known hypersensitivity to any of the study drugs or excipients, e.g., polysorbate 80 and Cremophor EL
Patients must not have any known previous or concurrent condition suggesting susceptibility to hypersensitivity or allergic reactions, including, but not limited to: known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies; patients with mild or seasonal allergies may be included after discussion with the study chairs
Known intolerance to either of the study drugs (or any of the excipients)
Allergy or hypersensitivity to cemiplimab or to any of its excipients;
Hypersensitivity to nivolumab, ipilimumab, or any of their excipients
Known allergy or hypersensitivity to any of the study drugs or their excipients.
History of allergy or hypersensitivity to any study drugs or their excipients
Known hypersensitivity to any of the excipients of ribociclib
History of hypersensitivity to durvalumab or tremelimumab or any excipients of these drugs.
Subject with a history of severe hypersensitivity reactions to any of the other excipients of the protocol IMPs (see Section 8.1.1);
Hypersensitivity to the active substance or to any of the excipients
Patient has a known hypersensitivity to any of the excipients of LEE011
Known hypersensitivity to drugs chemically related to tivozanib hydrochloride or sunitinib or their excipients
Known hypersensitivity to sunitinib or masitinib or to any of the excipients
Patients who have had hypersensitivity to paclitaxel or any of its excipients
Has a known severe hypersensitivity (? Grade 3) to any of the study chemotherapy agents and/or to any of their excipients.
Have previously participated in any study involving a checkpoint kinase 1 inhibitor or have hypersensitivity to the study drug or excipients.
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Known hypersensitivity to exemestane or its excipients
Hypersensitivity to nivolumab or any of its excipients.
Hypersensitivity to NKTR-214 or any of its excipients.
Participant has a known hypersensitivity to any of the excipients of H3B-6545.
Patient has a known hypersensitivity to any of the excipients of ribociclib or everolimus
Subjects with known allergies, hypersensitivity, or intolerance to niraparib or its excipients
Patient has a known hypersensitivity to any of the excipients of LEE011 or everolimus
Known hypersensitivity to afatinib or the excipients of any of the trial drugs
Known hypersensitivity to gemcitabine, taxanes or any of their excipients, or the patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of the product or comparator Summary of Product Characteristics or Prescribing Information. Possible hypersensitivity to napabucasin or one of the excipients which include the azo dyes sunset yellow and allura red.
History of severe hypersensitivity to study treatment excipients and additives or other monoclonal antibodies (mAbs) and/or their excipients.
Porphyria or known hypersensitivity to PhotofrinÂ® or porphyrin-like compounds or to any of its excipients
Participants with known allergies, hypersensitivity, or intolerance to ibrutinib or its excipients (refer to Investigator's Brochure)
Prior known hypersensitivity to any of the excipients of alpelisib
Known history, or suspected hypersensitivity to any excipients.
Known hypersensitivity to orteronel or to orteronel excipients, which are listed by formulation in the Investigator Brochure
Any known hypersensitivity to bevacizumab, erlotinib or other excipients of these drugs
EXCLUSION - PARTICIPANT: Participants with a history of hypersensitivity reactions to study agent or their excipients.
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Participants must not have hypersensitivity to nivolumab, urelumab, cabiralizumab or any of their excipients
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Has severe hypersensitivity (?Grade 3) to any study therapies including any excipients
Hypersensitivity to Ipilimumab and/or nivolumab or any of its excipients
Known hypersensitivity to gemcitabine (or other drug excipients) or chemically related drugs.
Known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients
Known intolerance or hypersensitivity to any of the products used in this study or their excipients.
Subjects with known hypersensitivity to study drugs or their excipients
Known hypersensitivity to nintedanib, nivolumab, ipilimumab, peanut or soy or any other trial drug, or their excipients
Known allergy or hypersensitivity to any of the study drugs or any of their excipients
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
Hypersensitivity (not including renal dysfunction or eye disorder) to CDV or to BCV or its formulation excipients
Patient has a known history of hypersensitivity to defibrotide or any of the excipients.
Hypersensitivity to ipilimumab or nivolumab or any of their excipients
Hypersensitivity to PBZ or any of its excipients
Has hypersensitivity to either study drug or any of the excipients.
Hypersensitivity to nivolumab, ipilimumab, or any of its excipients
Hypersensitivity to nivolumab or ipilimumab or any of its excipients
Hypersensitivity to durvalumab or tremelimumab, or any excipients on the formulation
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
Patients with known hypersensitivity to 5-azacitdine or MK3475 or any of their excipients
Known hypersensitivity to any of the excipients of ribociclib or bicalutamide.
Known hypersensitivity to any of the excipients of ribociclib (LEE-011)
Subjects with known hypersensitivity to study drugs or their excipients
Known hypersensitivity to pomalidomide, dexamethasone, or any excipients in elotuzumab, formulation, or recombinant protein
Known hypersensitivity to anetumab ravtansine, study drug classes or excipients in the formulation
Patients with a known hypersensitivity to any of the investigational agents or any of the excipients of the products
History of severe hypersensitivity reactions to paclitaxel or any of its excipients.
Patient has a known hypersensitivity to any of the excipients of ribociclib, aromatase inhibitors (such as letrozole) or fulvestrant
Hypersensitivity to nivolumab or lenalidomide or any of their excipients
Hypersensitivity to ruxolitinib or any of its excipients
Known hypersensitivity to any of the excipients of ribociclib or doxorubicin
Known hypersensitivity to afatinib or its excipients
Known hypersensitivity to GT0918 or its excipients.
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
Have known allergies, hypersensitivity, or intolerance to ARN-509 (apalutamide) or its excipients
Known hypersensitivity to letrozole or fulvestrant, or any of its excipients, or to any palbociclib excipients
Known hypersensitivity to exemestane or its excipients
Known hypersensitivity to nintedanib, any other trial drug, or their excipients
Known hypersensitivity to lenalidomide, dexamethasone, any excipients in the elotuzumab formulation (sodium citrate, citric acid, sucrose and polysorbate 80) or recombinant protein
Known history of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and dextran 40)
Patient has known hypersensitivity to any of the excipients of ribociclib
Known hypersensitivity to afatinib or the excipients of any of the trial drugs
Known hypersensitivity to S-equol or any of its excipients
Patients with a known hypersensitivity to BKM120 or to its excipients
Known hypersensitivity to bevacizumab or any of its excipients or any other study drug
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate, apalutamide or prednisone or their excipients
Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
Known allergies, hypersensitivity, or intolerance to the IP or its excipients
Has hypersensitivity to eribulin or any of the excipients
Allergies, hypersensitivity, or intolerance to niraparib or the corresponding excipients
Known hypersensitivity to ASN007 or its excipients;
History of allergy or hypersensitivity to any systemically administered antibody agent or its excipients
hypersensitivity to the active substance or to any of the excipients of study drug;
Known hypersensitivity to any of the excipients of INC280
Patients with a known hypersensitivity to BKM120 or to its excipients
Subjects to receive ofatumumab: hypersensitivity to ofatumumab or its excipients.
Known hypersensitivity to MMB, its metabolites, or formulation excipients
Patients with a known hypersensitivity to the testosterone cypionate or any of the excipients of the product
Known hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomab
Known hypersensitivity to irinotecan or its excipients.
Subject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients
Patients with hypersensitivity to mannitol are not eligible; patients who have known hypersensitivity to peanut or soya, any other trial drug, or their excipients, or to contrast media are not eligible
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
Known allergy or hypersensitivity to study treatment or any of the study drugs excipients.
Patient has a known hypersensitivity to any of the excipients of BYL719 and/or enzalutamide.
Patient has a known hypersensitivity to any of the excipients of BYL719 (alpelisib)
Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
A known hypersensitivity to abiraterone acetate, apalutamide, and prednisone and/or any of their excipients
Subjects who have a history of hypersensitivity to any of the study drugs or their excipients, or a history of severe hypersensitivity to any other antigen
Known hypersensitivity to ledipasvir, sofosbuvir, or formulation excipients
Patient has a known hypersensitivity to any of the excipients of buparlisib
Patient has a known hypersensitivity to ribociclib or excipients of tamoxifen
Patient has known hypersensitivity to any of the excipients of ribociclib
Patients with hypersensitivity to excipients of the study drug are not eligible
Known hypersensitivity to any of the study drugs or any of the ingredients or excipients of these drugs (e.g., polysorbate 80), including sensitivity to benzyl alcohol
Known hypersensitivity to afatinib, dasatinib, or the excipients of any of the trial drugs
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
Hypersensitivity to erlotinib or alectinib or to any of the excipients.
Intolerance to the excipients of the CTL019 cell product
Subject has a history of allergy or hypersensitivity to any study drugs or their excipients.
Subject has a known hypersensitivity to any of the excipients of nivolumab, cisplatin or romidepsin
Known hypersensitivity to any excipients of tesevatinib.
Known intolerance to the study drug or any of the excipients.
Participants who had a prior exposure to trabectedin or hypersensitivity to any of the excipients will not be excluded from receiving single-agent Doxil
Known allergies, hypersensitivity, or intolerance to Doxil, dexamethasone, or their excipients
Patient has a known hypersensitivity to any of the excipients of ribociclib
Prior demonstrated hypersensitivity, intolerance or allergy to abiraterone acetate, prednisone or their excipients
Have a known or suspected hypersensitivity to brigatinib or its excipients and/or crizotinib or its excipients.
Known hypersensitivity to momelotinib, its metabolites, or formulation excipients
Hypersensitivity to the active ingredient or any of the excipients including lactose.
History of severe hypersensitivity reaction to study treatments or their excipients.
Known allergies, hypersensitivity, or intolerance to talacotuzumab and daratumumab or their excipients
Known hypersensitivity to the study drugs (GS 5829, fulvestrant or exemestane), the metabolites, or formulation excipients
Known hypersensitivity to any of the study drugs or excipients
Patient has a known hypersensitivity to Ribociclib or any of its excipients.
Known hypersensitivity to any of the study drugs or excipients
Have known intolerance to the Test Article (ie, documented hypersensitivity AE to prior monoclonal antibody therapy, or to amatuximab or any of its excipients)
History of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and Dextran 40)
Known hypersensitivity to any of the excipients of the investigational products
Known hypersensitivity to the trial drugs or to their excipients
History of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and Dextran 40)
Known hypersensitivity to afatinib or letrozole or the excipients of any of the trial drugs.
Have a history of hypersensitivity to any study drugs or their excipients, or intolerance to hydration due to preexisting pulmonary or cardiac impairment, or intolerance to opioid pain medications, or a history of severe hypersensitivity to any other antigen.
Patient has a known hypersensitivity to any of the excipients of ribociclib or letrozole
Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients
Known intolerance or hypersensitivity to progesterone or its excipients
Patients with a known hypersensitivity to ribociclib or everolimus or to its excipients.
Prior treatment with nintedanib (BIBF1120); known hypersensitivity to nintedanib, peanut or soya or any other trial drug, their excipients or to contrast media
Subjects who have a history of hypersensitivity to any of the study drugs or their excipients, or a history of severe hypersensitivity to any other Antigen.
No known hypersensitivity to BIBF 1120, to its excipients or to contrast media
Patient has a known hypersensitivity to LEE011 or any of its excipients
History of hypersensitivity to any excipients in the investigational product.
Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study.
Patient has a known hypersensitivity to any of the excipients of BYL719
Hypersensitivity to chlorambucil, obinutuzumab, or venetoclax or to any of the excipients
Patients with a known hypersensitivity to BKM120 or to its excipients
Known hypersensitivity to any of the study drugs or excipients
Have a known or suspected hypersensitivity to brigatinib or its excipients.
Patients with a known hypersensitivity to BKM120 or its excipients
Have known allergies, hypersensitivity, or intolerance to AA or prednisone or their excipients
Subjects with hypersensitivity to study drugs or their excipients
Hypersensitivity to ofatumumab or its excipients
Known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies
Hypersensitivity to any of the study medications or any of the ingredients or excipients of these medications, including hypersensitivity to benzyl alcohol
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Have known allergies, hypersensitivity, or intolerance to enzalutamide or their excipients
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Patients with a known hypersensitivity to pazopanib or topotecan or to their excipients
A known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.
Patient with a history of severe hypersensitivity reaction to pemetrexed or docetaxel or any known excipients of these drugs.
Patients with a known hypersensitivity to BKM120 or to its excipients, or hypersensitivity to cetuximab
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Hypersensitivity to one of the trial drugs or the excipients.
Known severe hypersensitivity to tadalafil or any of the excipients of this product
Patients with a known hypersensitivity to vinorelbine or to its excipients
For Part C, have a known hypersensitivity to sorafenib or its excipients
Known intolerance to either of the study drugs (or any of the excipients)
Known allergies, hypersensitivity, or intolerance to TRC253 or its excipients.
Known intolerance to any of the study drugs (or any of the excipients)
Known hypersensitivity or intolerance to any of the active substances or excipients in the formulations for idelalisib, obinutuzumab, or chlorambucil
Known hypersensitivity to idelalisib, its metabolites, or formulation excipients
A known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.
Known hypersensitivity to the trial drugs, to their excipients or to contrast media
Patients with a known hypersensitivity to buparlisib or to its excipients
Hypersensitivity to erlotinib, crizotinib or to any of the excipients
Known hypersensitivity to afatinib (BIBW 2992) or the excipients of any of the trial drugs
History of hypersensitivity to any of the study drugs or to any excipients.
Known hypersensitivity to bevacizumab or any of its excipients or any other study drug
Known severe hypersensitivity to ketoconazole, calcitriol or any of the excipients of these products
Have known allergies, hypersensitivity, or intolerance to docetaxel or dexamethasone or their excipients
Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study
Patient has a known hypersensitivity to any of the excipients of PQR309.
Any contraindication, allergy, or hypersensitivity to rociletinib, trametinib, or excipients
Known hypersensitivity or intolerance to any of the active substances or excipients in the formulations for ENTO
Have known allergies, hypersensitivity, or intolerance to enzalutamide or niclosamide or their excipients
Known hypersensitivity to the study investigational medicinal product (IMP), the metabolites, or formulation excipients
Known allergies, hypersensitivity or intolerance to prednisone or excipients of abiraterone acetate or enzalutamide. History of hypersensitivity to docetaxel or polysorbate 80.
Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
Known allergy to any of the study drugs or their excipients.
Known hypersensitivity/allergy to fluconazole or itraconazole or their respective excipients.
Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
Known hypersensitivity to any of the study drugs or its excipients.
Known hypersensitivity to chlorambucil or any of its excipients
Have known allergies or hypersensitivity to abiraterone acetate or prednisone or their excipients
Known hypersensitivity to compounds related to orteronel or to orteronel excipients
Subjects with hypersensitivity (not renal dysfunction or eye disorder) to CDV or to CMX001 or its excipients.
Known hypersensitivity to BKM120 or to its excipients
Known hypersensitivity to the active substance or to any of the excipients in the vaccine
Patients with known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Known hypersensitivity to bevacizumab or any of its excipients, or any SOC drugs foreseen
Known allergies, hypersensitivity, or intolerance to trabectedin, dacarbazine, dexamethasone, or their excipients
Patients with a known hypersensitivity to BKM120 or to its excipients
Known significant hypersensitivity to study drugs or excipients
Hypersensitivity to recombinant proteins or excipients in elotuzumab, lenalidomide, or dexamethasone.
Known severe hypersensitivity to or any of the excipients of this product.
Patient has a known hypersensitivity to any of the excipients of BKM120
No known serious or severe hypersensitivity reaction to naloxegol or any of its excipients
Known hypersensitivity or idiosyncratic reaction to any of the study drugs (Sodium Cridanimod, megestrol acetate, lidocaine) and excipients;
Known intolerance to lenvatinib, everolimus (or other rapamycin derivatives), or any of the excipients
Known or suspected hypersensitivity or intolerance to fentanyl or hydromorphone or excipients in the study medications
History of hypersensitivity to any excipients in the quizartinib/placebo tablets;
Known hypersensitivity to ASN002 or its excipients;
Known hypersensitivity to recombinant ESAs or the excipients contained within the investigational product.
Patients with allergy, hypersensitivity or other contraindication to dapsone, sulfa antibiotics, or excipients of the dapsone gel product
Patient has a known history of hypersensitivity to defibrotide or any of the excipients.
Patient has a known hypersensitivity to the administration of rolapitant or its excipients
Subject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure)
Known intolerance to pritelivir and/or foscarnet or any of the excipients.
Hypersensitivity to decitabine, SGI-110, or SGI-110 excipients.
Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
Known intolerance to study drug (or any of the excipients).
Have severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients.
Has a known hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or T-DM1 or any of their excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
COHORT 1: Hypersensitivity to pembrolizumab or any of its excipients
COHORT 2: Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has a known severe hypersensitivity (? Grade 3) to pembrolizumab, its active substance and/or any of its excipients.
Has severe hypersensitivity (?Grade 3) to pembrolizumab and/or any of its excipients
Known hypersensitivity to any component of PVX-410, Hiltonol, Montanide, pembrolizumab, or excipients
Has severe hypersensitivity to pembrolizumab and/or any of its excipients and/or to ipilimumab and/or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
History of allergic reactions or hypersensitivity to pembrolizumab or any of its excipients
Has severe hypersensitivity (?Grade 3) to pembrolizumab and/or any of its excipients
Severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has a known hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients.
Patient has a known hypersensitivity to any of the excipients of bavituximab or pembrolizumab or monoclonal antibody
Hypersensitivity to pembrolizumab or any of its excipients
Has serious hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
Hypersensitivity to pembrolizumab or sunitinib or any of their excipients
Has hypersensitivity to pembrolizumab, epacadostat or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or lenvatinib or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Known hypersensitivity to pembrolizumab or any of its excipients
Has severe hypersensitivity (>= grade 3) to pembrolizumab or any of its excipients.
Has severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab, gadolinium, or ferumoxytol or any of their excipients
Had a severe hypersensitivity reaction to treatment with pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or paricalcitol or any of its excipients.
Has hypersensitivity to pembrolizumab, gadolinium, or ferumoxytol or any of their excipients
Has a known history of hypersensitivity to pembrolizumab or any of its excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has severe hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has known hypersensitivity to pembrolizumab and/or epacadostat or any of their excipients
Hypersensitivity to pembrolizumab or any of its excipients
Known hypersensitivity to BGB324, pembrolizumab, or any of their excipients.
Hypersensitivity to ibrutinib or pembrolizumab or any of their excipients
Severe hypersensitivity to pembrolizumab or any of its excipients
Known hypersensitivity to pembrolizumab or any of its excipients
History of hypersensitivity to pembrolizumab, docetaxel, gemcitabine, pemetrexed or any of their excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or lanreotide or any of their excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Known or presumed hypersensitivity to decitabine or pembrolizumab (or any of their excipients)
Hypersensitivity to pembrolizumab or ibrutinib or any of their excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to bevacizumab, cyclophosphamide, pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab, azacitidine, mannitol, or any of their excipients
Has a known hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab, vorinostat or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients.
Hypersensitivity to pembrolizumab, any of its excipients, paclitaxel, or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has hypersensitivity to pembrolizumab, docetaxel or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has severe hypersensitivity (?Grade 3) to pembrolizumab, MK-4280, or lenvatinib and/or any of its excipients
Severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients.
REGISTRATION TO TREATMENT (STEP 1): Patient must not have a history of hypersensitivity to pembrolizumab or any of its excipients
REGISTRATION TO TREATMENT (STEP 2): Patient must not have a history of hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or epacadostat or any of their excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab, epacadostat or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to MK-3475 (pembrolizumab) or any of its excipients;
Hypersensitivity to pembrolizumab, binimetinib, or any excipients of either drug
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has a known severe hypersensitivity (> Grade 3) to pembrolizumab, its active substance and/or any of its excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Has a known severe hypersensitivity to pembrolizumab, its active substance and/or any of its excipients
Severe hypersensitivity to any pembrolizumab excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Known hypersensitivity to pembrolizumab or any of its excipients and/or liposomal doxorubicin
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has known hypersensitivity to pembrolizumab or any of its excipients
Known hypersensitivity to pembrolizumab or any of its excipients.
Known allergy to pembrolizumab or any of its excipients.
Has severe hypersensitivity (? Grade 3) to any study treatment (pembrolizumab, cisplatin, or 5-FU) and/or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has severe hypersensitivity (Grade ?3) to pembrolizumab and/or any of its excipients
Has hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab, imatinib, or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of it's excipients.
Hypersensitivity to the active substance or any other excipients of the eribulin mesylate drug product, or severe hypersensitivity (>=Grade 3) to pembrolizumab and/or any of its excipients.
Hypersensitivity to pembrolizumab or any of its excipients
Has hypersensitivity to pembrolizumab or any of its excipients
Patients with known hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has a known severe hypersensitivity (? Grade 3) to pembrolizumab, its active substance and/or any of its excipients, or to any of the study chemotherapy agents and/or to any of their excipients.
Patients must not have a hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Has hypersensitivity to the active substance or to any of the excipients in BV or pembrolizumab.
Hypersensitivity to pembrolizumab or any of its excipients
Hypersensitivity to pembrolizumab or any of its excipients
Participants who have demonstrated intolerance to 125 mg of palbociclib are ineligible for the phase I portion
Previous treatment with palbociclib
Patients who have previously received palbociclib or other CDK4/6 inhibitors are not eligible
Previous exposure to a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib)
Prior treatment with palbociclib
Subjects must be receiving endocrine therapy consisting of 1) letrozole +/- palbociclib; or 2) exemestane +/ everolimus; or 3) fulvestrant +/- palbociclib; or 4) anastrozole; or 5) tamoxifen; pre-menopausal women must also be receiving a gonadotrophin releasing hormone (LHRH) agonist with endocrine therapy options 1 through 4; option 5 can be used without LHRH agonists for pre-menopausal women
Only for subjects enrolled in Arm 2 - Neratinib and palbociclib: any prior neuropathy should be back to baseline or grade 1.
Only for subjects enrolled in Arm 2 - Neratinib and palbociclib: patients who are taking medications with moderate or potent inhibitors or inducers of CYP450 3A4 should be off for 5 half-lives prior to starting palbociclib.
Scenario 2: the patient must have received an aromatase inhibitor or tamoxifen plus palbociclib as standard of care or received a CDK4/6 inhibitor (palbociclib or ribociclib or abemaciclib) as part of a clinical trial, and demonstrated evidence of disease progression; if the patient was enrolled in a randomized clinical trial involving ribociclib or abemaciclib or palbociclib (such as the MONALEESA or PALOMA series of trials), then it must be known after study discontinuation and unblinding that the patient received the investigational drug and not placebo; documentation of progression and duration of response on aromatase inhibitor or tamoxifen plus CDK 4/6 inhibitor should be provided whenever possible; no prior fulvestrant allowed
Known or possible hypersensitivity to palbociclib, fulvestrant, goserelin (if applicable) or to any of their excipients
Known or possible hypersensitivity to palbociclib (CTCAE version [V] 4.03)
Known or possible hypersensitivity to fulvestrant, or palbociclib or any of their excipients.
Known severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib/placebo excipients or to endocrine treatments.
Female subjects of childbearing potential should be willing to use two methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year\r\n* Cohort 1 (accrual to 6 patients) is for patients who had ongoing stable disease (SD) on letrozole + palbociclib, enrolled on prior version of eligibility criteria to receive pembrolizumab after obtaining stable disease on letrozole + palbociclib; these patients must have been on treatment with letrozole and palbociclib for 6 months with SD per RECIST 1.1; received up to 3 lies of previous therapy including endocrine and/or chemotherapy in advanced setting prior to initiation of letrozole and palbociclib; no grade 3 toxicities except alopecia
No known severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib excipients or to endocrine treatments.
Participants who have discontinued prior palbociclib for toxicity, or have needed more than one dose or schedule reduction for toxicity from prior palbociclib therapy; if a participant required a single dose reduction during prior palbociclib therapy and tolerated it well, for example prior dosing at 100 mg qd 3 weeks on 1 week off schedule, than that dose may be selected for this trial
Previous treatment with palbociclib, abemaciclib, ribociclib or other investigational CDK4/6 inhibitors
Palbociclib can be started at week 4, if indicated
Must be candidates to receive endocrine therapy and palbociclib or ribociclib as first-line treatment for their advanced disease. Patients will be considered eligible for study enrollment if they have started on treatment with a standard dose and schedule of palbociclib or ribociclib and endocrine therapy (aromatase inhibitor or fulvestrant) as long as they have not started palbociclib or ribociclib treatment for longer than 4 weeks from time of study enrollment, have sufficient tissue to perform the proposed tissue analysis and must meet all other eligibility criteria. Endocrine therapy can be initiated up to 4 weeks prior to starting palbociclib or ribociclib.
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Patients who have a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent are not eligible
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
History of allergic reaction/hypersensitivity to any of the study medications, their analogues or excipients in the various formulations
Known allergy to any of the study medications, their analogues or excipients in the various formulations
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues or excipients in the various formulations
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues or excipients in the various formulations
Known allergy to any of the study medications, their analogs, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent; specifically, prior desquamating rash or erythema nodosum during prior thalidomide or other similar agents
Known allergy to any of the study medications, their analogues or excipients in the various formulations
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent; patient cannot be allergic to boron
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Have known severe intolerance to or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous immunoglobulin preparations; any history of anaphylaxis; prior history of human anti-human antibody response; known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to ixazomib, its analogues, or excipients in the various formulations of ixazomib
Known allergy to any of the study medications, their analogues or excipients in the various formulations
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
No history of allergic reaction/hypersensitivity to any of the study medications, their analogues or excipients in the various formulations
Known allergy to any of the study medications, their analogues, or excipients in the various formulations
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
Known allergy to any of the study medications, their analogues or excipients in the various formulations
History of allergic reaction/hypersensitivity to any of the study medications, their analogues or excipients in the various formulations
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Patients with known allergy to boron or boron-containing products, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Subjects with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Subjects with a hypersensitivity to sirolimus.
Known intolerance to study drug (or any of the excipients) and/or known hypersensitivity to rapamycins (eg, sirolimus, everolimus, temsirolimus) or any of the excipients
Patients with a known hypersensitivity to everolimus or other rapamycins (e.g. sirolimus, temsirolimus)
Known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Known intolerance or hypersensitivity to rapamycin analogs (e.g. sirolimus, temsirolimus)
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
History of hypersensitivity to sirolimus, temsirolimus, everolimus
Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Patients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
Patients with a known hypersensitivity to RAD001(everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients
Patients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
Patients must not have any known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Known intolerance or hypersensitivity to Everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Known hypersensitivity to RAD001 or other rapamycins (sirolimus, temsirolimus, deforolimus)
Patients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
Patients with a known hypersensitivity to everolimus (RAD001) or other rapamycins (sirolimus, temsirolimus) or to its excipients
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Patients with a known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients
Known hypersensitivity to sirolimus.
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients, or to bortezomib, boron, or mannitol
Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
Known hypersensitivity to thalidomide or everolimus (including other rapamycins, sirolimus and temsirolimus)
Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
Known hypersensitivity to sirolimus
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus);
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
FOR ALL PHASES (Ib AND II): Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulation
Known or suspected allergy or hypersensitivity to regorafenib, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulation
Known or suspected allergy or hypersensitivity to any of the study drug classes
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known hypersensitivity to study drug, study drug classes or excipients of the formulation.
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.
Known or suspected grade 3 allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected grade 3 allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea); a) history of organ allograft (including corneal transplant); b) known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial; c) any malabsorption condition; d) any condition which, in the investigatorâs opinion, makes the subject unsuitable for trial participation; e) substance abuse, medical, psychological or social conditions that may interfere with the subjectâs participation in the study or evaluation of the study results
Patients must have no known allergies to exemestane, entinostat, or medications that have a benzamide structure (e.g., tiapride, remoxipride, clebropride)
Known allergies to carfilzomib or Captisol
History of any drug allergies or significant adverse reactions to any of the components of SM-88.
Patients with known and documented allergies to any of the penicillins, cephalosporins, or beta-lactamase inhibitors
Known allergies to medical adhesives or hydrogel
Known allergies to medical adhesives or hydrogel
History of allergies to any active or inactive ingredients of atezolizumab.
Patients who cannot tolerate pneumocystis jirovecii pneumonia (PJP) prophylaxis (i.e., known Bactrim and pentamidine allergies)
Patients with known or suspected allergies to any component of the vaccine.
ALLERGIES AND ADVERSE DRUG REACTION
Known allergies to medical adhesives or hydrogel
Patients with known contrast allergies requiring pre-medication with steroids
Known allergies, hypersensitivity or intolerance to apalutamide, abiraterone acetate, prednisone, or GNRH agonist or GNRH antagonist
Subjects with three or more drug allergies from separate drug classes
History of multiple drug allergies or intolerance to subcutaneous injections
Subjects with three or more drug allergies from separate drug classes
Allergies, hypersensitivity, or intolerance to prednisone, LHRH analog or excipients of prednisone LHRH analog, abiraterone acetate and apalutamide.
Allergies to any vaccine, that after discussion with Immunovaccine, are serious enough to warrant exclusion from this study
Prior use of niclosamide or allergies to niclosamide
Allergies and adverse drug reaction
Allergies to Lidocaine or Novocain
Allergies to imaging dyes
Documented penicillin or cephalosporin allergies
Subjects with any underlying conditions, which would contraindicate therapy with, study treatment (or allergies to reagents used in this study)
Known allergies to any of the components of the investigational treatment regimen or required ancillary treatments
Patients with NSAIDs allergies, known lactose allergy, a history of recent gastrointestinal (GI) bleed (less than 2 weeks), and those who are on therapeutic dose anticoagulants will be excluded from this protocol
Patients with allergies to any component of the vaccine will be excluded from the protocol
Subjects must not have allergies to any compounds similar to CDB-4124
Allergies to lidocaine or marcaine
Allergies to imaging dyes
Known history of allergies or sensitivities to gentamicin.
Patients with allergies to isosulfan blue or technetium, which would preclude sentinel node mapping
Antibiotic allergies that would preclude treatment for a C. novyi-NT infection
Participants with known or suspected allergies to any component of the vaccine
Known allergies to clofarabine, melphalan, sirolimus or tacrolimus
Allergies or hypersensitivities to monoclonal antibodies, BMS-986012 or related compounds, including fucosyl-GM1 vaccine and Nivolumab
Subjects with any known severe allergies (e.g. anaphylaxis) to any active or inactive ingredients in the study drugs.
Known allergies, hypersensitivity, or intolerance to any form of heparin or azacitidine
No eating disorders, food allergies or intolerances
Any prior allergies to curcumin or turmeric
Known allergies to any of the components of the investigational treatment regimen or required ancillary treatments
Any history of allergies to grapes or grape seed
Known allergies, hypersensitivity or intolerance to abiraterone acetate, prednisone or degarelix
Subjects with any underlying conditions which would contraindicate therapy with study treatment (or allergies to reagents)
Subject has any underlying conditions, which would contraindicate therapy with study treatment (or allergies to reagents used in this study)
Antibiotic allergies that would preclude treatment for a C. novyi-NT infection.
Allergies to excipients in the study drug.
Hypersensitivities, allergies or contraindications to study medications; intolerance of medical tape or sticking plaster.
Allergies to temozolomide, dacarbazine, IgG containing agents
Allergies and Adverse Drug Reaction
Allergies to any component of the vaccine
Known allergies, hypersensitivity, or intolerance to dacarbazine does not apply
Allergies to eggs, lecithin or soy products.
No allergies to and not currently using varenicline
Significant food allergies which would make the subject unable to consume the food provided (soy or nut allergy)
Patients with known allergies to egg products, neomycin, or tetanus toxoid
Subjects with allergies to any supplements.
Patients with allergies to any of the ingredients in the nutritional supplement
Milk protein intolerance/allergies (lactose intolerance is acceptable)
Known allergies or intolerance to cisplatin and similar platinum-containing compounds
Allergic history, including anaphylaxis or severe allergies to products in study serum or placebo
Has known allergies or intolerance to brilacidin, cisplatin or carboplatin
Patients will be excluded from the trial if they have had a history of allergies or intolerance to fructooligosaccharides or the components of FOS including fructose and glucose
Known allergies or intolerance to cisplatin and similar platinum-containing compounds
Known allergies, hypersensitivity, or intolerance to any of the study medications.
Cutaneous photosensitivity to wavelengths of 400-450 nm, porphyria or known allergies to porphyrins
All patients who are have known allergies or are sensitive to silver and acrylic adhesives
Allergies to multiple food items or nutritional supplements
History of food allergies and/or major dietary restrictions
Subjects should not have known allergies to cruciferous vegetables
No known allergies to tree nuts (i.e. almonds)
Subjects with three or more drug allergies from separate drug classes
Subjects with three or more drug allergies from separate drug classes
No known allergies to contrast material
No known allergies to contrast material
Known allergies to contrast material
History of allergies to iodides
Subjects with a history of iodide allergies
Allergy to gadolinium or other severe drug allergies
Subjects with three or more drug allergies from separate drug classes
Patients with allergies to iodinated contrast not amenable to pre-medication
History of allergies and adverse drug reaction to study drug components
Subjects with three or more drug allergies from separate drug classes
Allergies to study medications, such as, lidocaine, Versed, or Cetacaine
Allergies and Adverse Drug Reaction a. Subjects with known hypersensitivity to excipients of Dasatinib tablets
No history of hypersensitivity active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib
History of hypersensitivity to active or inactive excipients of AZD5363, fulvestrant and enzalutamide or drugs with a similar chemical structure or class to these agents
History of hypersensitivity to any active or inactive ingredient of HS-10296 or to a drug with a similar chemical structure or class to HS-10296.
History of hypersensitivity to AZD4635 or drugs with a similar chemical structure or class to AZD4635.
History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib
History of hypersensitivity of osimertinib (or active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib)
History of hypersensitivity to AZD9291 (or drugs with a similar chemical structure or class to AZD9291) or any excipients of these agents
History of hypersensitivity to osimertinib (or drugs with a similar chemical structure or class to osimertinib) or any excipients of these agents
Any previous treatment with AZD1775 or allergic reactions to excipients of AZD1775
History of hypersensitivity active or inactive excipients of AZD9291 (osimertinib) or drugs with a similar chemical structure or class to AZD9291 (osimertinib)
Patients must not have a history of hypersensitivity to active or inactive excipients of AZD4547 or drugs with a similar chemical structure or class to AZD4547
History of hypersensitivity to active or inactive excipients of AZD2014 or drugs with a similar chemical structure or class to AZD2014
Known history of hypersensitivity to active or inactive excipients of HM61713 or drugs with a similar chemical structure of HM61713
Patients with known hypersensitivity to olaparib, AZD5363, AZD2014 or any of their excipients; patients with a history of hypersensitivity to drugs with a similar chemical structure or class to olaparib, AZD5363, or AZD2014
History of hypersensitivity to active or inactive excipients of olaparib or abiraterone or drugs with a similar chemical structure or class to olaparib or abiraterone.
AZD9291 in the present study (ie, dosing with AZD9291 previously initiated in this study).
History of hypersensitivity (> Grade 2) to active or inactive excipients of AZD2014, drugs containing Cremophor, taxanes or structurally/chemically similar drugs
A bad reaction to AZD5363 or any drugs similar to it in structure or class.
History of hypersensitivity to active or inactive excipients of AZD2014 or drugs with a similar chemical structure or class to AZD2014
